FLUOCINONIDE ACETONIDE
Clinical safety rating: safe
No significant drug interactions Systemic absorption can occur with extensive use.
Fluocinonide acetonide is a corticosteroid that binds to glucocorticoid receptors, modulating gene transcription to induce anti-inflammatory, antipruritic, and vasoconstrictive effects. It inhibits phospholipase A2, reducing arachidonic acid release and subsequent prostaglandin and leukotriene synthesis.
| Metabolism | Primarily hepatic via CYP3A4; undergoes extensive first-pass metabolism. |
| Excretion | Primarily hepatic metabolism with renal excretion of inactive metabolites; <1% unchanged drug in urine; biliary/fecal excretion accounts for ~60% of metabolites. |
| Half-life | Terminal elimination half-life is approximately 48-72 hours; prolonged in hepatic impairment due to reduced clearance; duration of action at skin sites persists up to 4-6 hours post-application. |
| Protein binding | ~90-95% bound to plasma proteins, primarily albumin and corticosteroid-binding globulin (CBG). |
| Volume of Distribution | Approximately 0.7 L/kg (highly variable due to lipophilicity); reflects extensive tissue distribution, particularly to skin and adipose tissue. |
| Bioavailability | Topical: <1% systemic bioavailability with intact skin (varies by site, occlusion, and lesion severity); up to 5-10% with damaged skin or occlusion; oral not commercially available; parenteral not indicated. |
| Onset of Action | Topical: 1-2 hours for vasoconstriction (blanching); anti-inflammatory effect begins within 2-3 days of regular application. |
| Duration of Action | Topical: Anti-inflammatory effect lasts 6-12 hours after single application; therapeutic effect maintained with twice-daily dosing; systemic duration limited by adrenal suppression risk with prolonged use. |
Apply a thin film to affected area 1 to 3 times daily, depending on severity. Maximum: 2 weeks continuous use. Not for use on face, groin, or axillae. Dispense 15-60 g per application.
| Dosage form | OIL |
| Renal impairment | No dosage adjustment necessary for topical use. Systemic absorption is minimal; no specific GFR-based modifications required. |
| Liver impairment | No dosage adjustment necessary for topical use. Systemic absorption is minimal; no specific Child-Pugh based modifications required. |
| Pediatric use | Apply a thin film to affected area 1 to 2 times daily. Limit treatment duration to 5 days. Use lowest potency and smallest amount. Not recommended in children under 2 years of age. |
| Geriatric use | Use with caution due to thinner skin and increased risk of skin atrophy and systemic absorption. Apply sparingly, limit treatment area, and avoid prolonged use. No specific dose adjustment. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
No significant drug interactions Systemic absorption can occur with extensive use.
| FDA category | Animal |
| Breastfeeding | Excretion into breast milk is unknown after topical application, but systemic absorption is low. Caution with prolonged use on large areas or under occlusion. M/P ratio not available. Use lowest effective dose and avoid application to breast area prior to nursing. Generally considered compatible with breastfeeding. |
| Teratogenic Risk |
■ FDA Black Box Warning
None
| Common Effects | Skin atrophy |
| Serious Effects |
["Hypersensitivity to fluocinonide or any component","Untreated bacterial, viral, or fungal skin infections","Perioral dermatitis"]
| Precautions | ["Systemic absorption may cause reversible HPA axis suppression, Cushing's syndrome, hyperglycemia, and glucosuria","Prolonged use may increase risk of local and systemic infections","Avoid use on face, axillae, and groin due to higher risk of skin atrophy","Discontinue if irritation develops","Use caution in pediatric patients due to greater susceptibility to systemic toxicity","Can mask signs of infection"] |
Loading safety data…
| Topical corticosteroids, including fluocinonide acetonide, are generally considered low risk for teratogenicity when used at recommended doses. Systemic absorption is minimal, but high potency or extensive use may increase risk. First trimester: no clear evidence of major malformations; avoid excessive use. Second and third trimesters: risk of intrauterine growth restriction with prolonged high-dose use; use lowest potency and shortest duration possible. |
| Fetal Monitoring | Monitor for signs of maternal adrenal suppression or Cushing's syndrome with prolonged high-dose use. Fetal monitoring for growth restriction if high-potency or extensive use during second/third trimester. Assess skin integrity and signs of infection at application site. |
| Fertility Effects | No known adverse effects on fertility from topical corticosteroids. Systemic corticosteroids can disrupt ovulation, but this is unlikely with topical use at recommended doses. No specific fertility studies reported for fluocinonide acetonide. |